Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Joly

Showing results (531-540 of 569) with videos related to

Pageof 57
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|March 24, 2018
Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the « OBJECTIFS PEAU » studyM-A Richard, F Corgibet, M Beylot-Barry, et al.
Molecular Genetics and Metabolism|March 23, 2005
Thymidine phosphorylase gene mutations in patients with mitochondrial neurogastrointestinal encephalomyopathy syndromeA Slama, C Lacroix, V Plante-Bordeneuve, et al.
The British Journal of Dermatology|February 4, 2015
Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 casesA Fauconneau, A Pham-Ledard, D Cappellen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 17, 2019
Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQM Masson Regnault, J Castañeda-Sanabria, M H T Diep Tran, et al.
The British Journal of Dermatology|May 8, 2013
Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patientsF Julia, T Petrella, M Beylot-Barry, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
Blood|May 26, 1999
Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous LymphomasF Grange, G Hedelin, P Joly, et al.
Clinical and Experimental Immunology|June 16, 2004
Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceusM Kallel Sellami, M Ben Ayed, H Mouquet, et al.
The British Journal of Dermatology|June 3, 2009
Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective allelesO Abida, M Zitouni, M Kallel-Sellami, et al.
Annales De Dermatologie Et De Venereologie|February 12, 2013
[Changes in the incidence and mortality rates of malignant melanoma in the Seine-Maritime region over a 20-year period]C Le Blanc, C Corven, P Courville, et al.
Pageof 57

Showing results (531-540 of 569) with videos related to

Sort By:
Pageof 57
Journal of the European Academy of Dermatology and Venereology : JEADV|March 24, 2018
Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the « OBJECTIFS PEAU » studyM-A Richard, F Corgibet, M Beylot-Barry, et al.
Molecular Genetics and Metabolism|March 23, 2005
Thymidine phosphorylase gene mutations in patients with mitochondrial neurogastrointestinal encephalomyopathy syndromeA Slama, C Lacroix, V Plante-Bordeneuve, et al.
The British Journal of Dermatology|February 4, 2015
Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 casesA Fauconneau, A Pham-Ledard, D Cappellen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 17, 2019
Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQM Masson Regnault, J Castañeda-Sanabria, M H T Diep Tran, et al.
The British Journal of Dermatology|May 8, 2013
Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patientsF Julia, T Petrella, M Beylot-Barry, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
Blood|May 26, 1999
Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous LymphomasF Grange, G Hedelin, P Joly, et al.
Clinical and Experimental Immunology|June 16, 2004
Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceusM Kallel Sellami, M Ben Ayed, H Mouquet, et al.
The British Journal of Dermatology|June 3, 2009
Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective allelesO Abida, M Zitouni, M Kallel-Sellami, et al.
Annales De Dermatologie Et De Venereologie|February 12, 2013
[Changes in the incidence and mortality rates of malignant melanoma in the Seine-Maritime region over a 20-year period]C Le Blanc, C Corven, P Courville, et al.
Pageof 57